Overcoming resistance: Virologic response to a salvage regimen with the combination of ritonavir plus indinavir

HIV Clinical Trials

Volumn 4, Issue 1, 2003, Pages 21-28

  Casado, Jose L ^a   Moreno, Ana ^a   Martílda, Paloma ^a   Sabido, Raquel ^a   Pinheiro, Sofía ^a   Bermudez, Elena ^a   Antela, Antonio ^a   Dronda, Fernando ^a   Perez Elías, María J ^a   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Pharmacokinetics; Protease inhibitors; Resistance

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS LOAD; VIRUS RESISTANCE;

ADULT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; MALE; MUTATION; RITONAVIR; RNA, VIRAL; SALVAGE THERAPY;

EID: 0037224471     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/KDUH-FJC3-NGYH-XPWY     Document Type: Article

References (22)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med. 1998;338:853-860
2. Casado JL, Perez-Elías MJ, Antela A, et al. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS. 1998;12:F131-135.
3. d'Arminio Monforte A, Cozzi Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000;14:499-507.
4. Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. JAMA. 1998;279:1984-1991.
5. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760-766.
6. Baxter JD, Mayers DL, Wentworth DN, et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-F93.
7. Durant J, Clevenberg P, Halfon P, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-2199.
8. Schmidt B, Walter H, Moschik B, et al. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS. 2000;14:1731-1738.
9. Rice H, Zolopa A, Shulman N, Condra J. Determination of clinically relevant phenotypic resistance breakpoints for indinavir/ritonavir containing antiretroviral regimens. In: Program and abstracts of the Fifth International Workshop on HIV Drug Resistance and Treatment Strategies; June 4-8, 2001; Scottsdale, Arizona. Abstract 41.
10. Condra JH, Petropoulos CJ, Ziermann R, et al. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis. 2000;182:758-765.
11. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1 infected individuals. AIDS. 1999;13:F90-F99.
12. Kempf D, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41:654-660.
13. van Praag RME, Weverling GJ, Portergies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS. 2000;14:1187-1194.
14. Rockstroh JK, Bergmann F, Wiesel W, et al. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. AIDS. 2000;14:1181-1185.
15. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV infected patients treated with genotypic guided therapy: pharmacological data from the Viradapt study. AIDS. 2000;14:1333-1339.
16. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virologic treatment failure in HIV-1 infected patients on indinavir containing triple therapy. Antivir Ther. 1998;3:215-220.
17. Casado JL, Moreno A, Sabido R, et al. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response. HIV Clin Trials. 2000;1(1):13-19.
18. Kawle SP, Remmel RP, Weller OD, Fletcher CV. A simultaneous HPLC assay for quantification of indinavir, saquinavir, ritonavir, and nelfinavir in human plasma. In: Program and abstracts of the Fifth Conference on Retroviruses and Opportunistic Infections; 1998; Chicago, Illinois.
19. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2000;283:381-390.
20. The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS. 2001;15:309-320.
21. Dieleman JP, Gyssens IC, van der Ende M, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-478.
22. Gatell JM, Lange J, Arnaiz JA, et al. A randomized study comparing continued indinavir (800 mg tid) to indinavir/ritonavir (800/100 mg bid) in HIV patients having achieved viral load with indinavir plus two nucleosides analogues: the BID efficacy and safety trial (BEST). In: Program and abstracts of the XIII International AIDS Conference; July 9-14, 2000; Durban. Abstract WeOrB484.